Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/235112
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest |
Autor: | Al Musaimi, Othman; Al Shaer, Danah; Albericio, Fernando CSIC ORCID; de la Torre, Beatriz G. | Palabras clave: | Belantamab mafodotin-blmf 64Cu-DOTATATE drugs FDA 68Ga-PSMA-11 lumasiran Setmelanotide Oligonucleotides Peptides Viltolarsen |
Fecha de publicación: | 11-feb-2021 | Editor: | Molecular Diversity Preservation International | Citación: | Pharmaceuticals 14(2): 145 (2021) | Resumen: | 2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects. | Versión del editor: | https://doi.org/10.3390/ph14020145 | URI: | http://hdl.handle.net/10261/235112 | DOI: | 10.3390/ph14020145 | E-ISSN: | 1424-8247 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IQAC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
pharmaceuticals-14-00145-v2.pdf | 1,73 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
26
checked on 10-abr-2024
SCOPUSTM
Citations
50
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
43
checked on 25-feb-2024
Page view(s)
98
checked on 19-abr-2024
Download(s)
265
checked on 19-abr-2024